Cohance Lifesciences Taps Ex-Cipla Chief Umang Vohra; Shares Jump 20%

[{ "selector": ".mjrux-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateX(calc(360px - 291px)) scale(0.15)", "opacity": "1", "visibility" :"visible"}, {"offset": 1, "transform": "translateX(0px) scale(1)", "opacity": "1", "visibility" :"visible"} ] }, { "selector": ".bcfzw-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "opacity": 0, "visibility" :"visible"}, {"offset": 1, "opacity": "1", "visibility" :"visible"} ] }]

High-Profile Appointment

Cohance Lifesciences appointed Umang Vohra, former CEO of Cipla, as Executive Chairman effective May 1, 2026, and as Group CEO effective May 20, 2026, sending shares surging 20% on the announcement.

[{ "selector": ".ofepp-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateY(-15px)", "opacity": "1", "visibility" :"visible"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1", "visibility" :"visible"} ] }, { "selector": ".zmznj-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 550px))", "opacity": "1", "visibility" :"visible"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1", "visibility" :"visible"} ] }]

Vohra's Stellar Track Record

Vohra joined Cipla in 2015 and became CEO in 2016, overseeing a decade of strategic expansion, portfolio diversification, and operational strengthening across global markets before stepping down on March 31, 2026.

[{ "selector": ".ilgdw-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateY(-15px)", "opacity": "1", "visibility" :"visible"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1", "visibility" :"visible"} ] }, { "selector": ".oiwrr-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 550px))", "opacity": "1", "visibility" :"visible"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1", "visibility" :"visible"} ] }]

Smooth Leadership Transition

Outgoing Executive Chairman Vivek Sharma will step down on April 30, 2026, and transition into a Special Advisor role for nine months to ensure business continuity during the handover to Vohra's leadership team.

[{ "selector": ".rjjdn-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateY(-15px)", "opacity": "1", "visibility" :"visible"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1", "visibility" :"visible"} ] }, { "selector": ".bupnf-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 550px))", "opacity": "1", "visibility" :"visible"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1", "visibility" :"visible"} ] }]

Strategic CDMO Focus

Cohance has established a strong market position in complex chemistry, ADCs, oligonucleotides, and advanced process R&D, supported by over 400 R&D scientists and integrated research centres serving global pharmaceutical innovators.

[{ "selector": ".rlfsc-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateY(-15px)", "opacity": "1", "visibility" :"visible"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1", "visibility" :"visible"} ] }, { "selector": ".qaorm-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 550px))", "opacity": "1", "visibility" :"visible"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1", "visibility" :"visible"} ] }]

ESOP 2026 Also Approved

Alongside the leadership change, the board also approved a new Employee Stock Option Plan (ESOP) 2026, signalling the company's intent to attract and retain top-tier talent as it enters its next phase of transformation and global growth.

[{ "selector": ".lttrq-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateY(-15px)", "opacity": "1", "visibility" :"visible"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1", "visibility" :"visible"} ] }, { "selector": ".selof-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 550px))", "opacity": "1", "visibility" :"visible"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1", "visibility" :"visible"} ] }]

With Our Subscription Plans

[{ "selector": ".bnxrw-a", "duration": "500ms", "fill": "forwards", "delay": "0ms", "keyframes": [ {"offset": 0, "opacity": 0, "visibility" :"visible"}, {"offset": 1, "opacity": "1", "visibility" :"visible"} ] }, { "selector": ".msskk-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "opacity": 0, "visibility" :"visible"}, {"offset": 1, "opacity": "1", "visibility" :"visible"} ] }, { "selector": ".uznts-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateX(-299px)", "opacity": "1", "visibility" :"visible" }, {"offset": 1, "transform": "translateX(0)", "opacity": "1", "visibility" :"visible"} ] }, { "selector": ".kxtnp-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateY(-33px)", "opacity": "1", "visibility" :"visible"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1", "visibility" :"visible"} ] }] Open Demat A/C

Cohance Lifesciences Taps Ex-Cipla Chief Umang Vohra; Shares Jump 20%

High-Profile Appointment Cohance Lifesciences appointed Umang Vohra, former CEO of Cipla, as Executive Chairman effective May 1, 2026, and as Group CEO effective May 20, 2026, sending shares surging 20% on the announcement.

Vohra's Stellar Track Record Vohra joined Cipla in 2015 and became CEO in 2016, overseeing a decade of strategic expansion, portfolio diversification, and operational strengthening across global markets before stepping down on March 31, 2026.

Smooth Leadership Transition Outgoing Executive Chairman Vivek Sharma will step down on April 30, 2026, and transition into a Special Advisor role for nine months to ensure business continuity during the handover to Vohra's leadership team.

Strategic CDMO Focus Cohance has established a strong market position in complex chemistry, ADCs, oligonucleotides, and advanced process R&D, supported by over 400 R&D scientists and integrated research centres serving global pharmaceutical innovators.

ESOP 2026 Also Approved Alongside the leadership change, the board also approved a new Employee Stock Option Plan (ESOP) 2026, signalling the company's intent to attract and retain top-tier talent as it enters its next phase of transformation and global growth.